PTC Therapeutics rallies after unveiling $500 mln stock buyback

By Reuters News

** PTC Therapeutics' PTCT.O shares rally 8.7% to more than 1-month high of $66.20 early Tues as it looks to buy back its stock

** PTCT on course for biggest one-day pct gain since 14.3% advance on May 8

** Warren, New Jersey-based firm early Tues announced $500 mln share repurchase program

** Co focuses on developing treatments for rare disorders including Duchenne muscular dystrophy, Friedreich's ataxia and Huntington's disease

** It has ~83.5 mln shares outstanding for ~$5.1 bln market cap as of Mon

** With the advance, shares down ~13% YTD vs Nasdaq Biotech index's .NBI ~28.5% rise

** 13 of 15 analysts rate the stock "strong buy" or "buy", 2 "hold"; median PT $98, according to LSEG data

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.